Literature DB >> 12696377

[Human African trypanosomiasis in Ivory Coast: biological characteristics after treatment. 812 cases treated in the Daloa focus (Ivory Coast)].

T W Miezan1, N N Dje, F Doua, F Boa.   

Abstract

The treatment and post therapeutic follow up of patients diagnosed with HAT are important for HAT control. A longitudinal survey was implemented in the focus of Daloa (Côte d'Ivoire). A total of 812 patients infected with Trypanosoma brucei gambiense in meningoencephalitic stage and treated with melarsoprol were included, this study pointed out the biological characteristics of patients after treatment. The relapse occurs between 1 and 24 months after treatment. It is essentially neurological, and characterised by the presence in the CSF of antibodies, by the increase of cell count compared with value immediately after treatment, or by the presence of trypanosomes. The cure can be confirmed from 18 months after treatment, and is characterised by the absence of antibodies and trypanosomes in the CSF, by a normal cell count and a normal proteinorachy. Biological scares were recorded on some of the patients after 18 months of follow up, but no relapse occurred among them.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12696377

Source DB:  PubMed          Journal:  Bull Soc Pathol Exot        ISSN: 0037-9085


  5 in total

1.  A CATT negative result after treatment for human African trypanosomiasis is no indication for cure.

Authors:  Veerle Lejon; Dieudonné Mumba Ngoyi; Marleen Boelaert; Philippe Büscher
Journal:  PLoS Negl Trop Dis       Date:  2010-01-26

2.  Treatment failure related to intrathecal immunoglobulin M (IgM) synthesis, cerebrospinal fluid IgM, and interleukin-10 in patients with hemolymphatic-stage sleeping sickness.

Authors:  Veerle Lejon; Jo Robays; François Xavier N'Siesi; Dieudonné Mumba; Annemie Hoogstoel; Sylvie Bisser; Hansotto Reiber; Marleen Boelaert; Philippe Büscher
Journal:  Clin Vaccine Immunol       Date:  2007-04-11

3.  Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis.

Authors:  Jose R Franco; Pere P Simarro; Abdoulaye Diarra; Jose A Ruiz-Postigo; Mireille Samo; Jean G Jannin
Journal:  Res Rep Trop Med       Date:  2012-08-23

4.  Diagnostic accuracy of PCR in gambiense sleeping sickness diagnosis, staging and post-treatment follow-up: a 2-year longitudinal study.

Authors:  Stijn Deborggraeve; Veerle Lejon; Rosine Ali Ekangu; Dieudonné Mumba Ngoyi; Patient Pati Pyana; Médard Ilunga; Jean Pierre Mulunda; Philippe Büscher
Journal:  PLoS Negl Trop Dis       Date:  2011-02-22

5.  Trypanosome SL-RNA detection in blood and cerebrospinal fluid to demonstrate active gambiense human African trypanosomiasis infection.

Authors:  Ipos Ngay Lukusa; Nick Van Reet; Dieudonné Mumba Ngoyi; Erick Mwamba Miaka; Justin Masumu; Pati Patient Pyana; Wilfried Mutombo; Digas Ngolo; Vincent Kobo; Felix Akwaso; Médard Ilunga; Lewis Kaninda; Sylvain Mutanda; Dieudonné Mpoyi Muamba; Olaf Valverde Mordt; Antoine Tarral; Sandra Rembry; Philippe Büscher; Veerle Lejon
Journal:  PLoS Negl Trop Dis       Date:  2021-09-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.